Serum melatonin levels and in a sample of Iranian patients with migraine.
Headache
Melatonin
Migraine
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
02 Oct 2024
02 Oct 2024
Historique:
received:
01
07
2024
accepted:
16
09
2024
medline:
3
10
2024
pubmed:
3
10
2024
entrez:
2
10
2024
Statut:
epublish
Résumé
Migraine, a complex disorder, is characterized by recurrent headache episodes. The production of melatonin in the pineal gland, which is crucial for controlling circadian rhythms and sleep-wake cycles, is altered in various conditions, including neurological disorders such as migraine. Recent studies underscore the significance of serum melatonin levels in patients with chronic and episodic migraine, the focus of this study. This case‒control study, conducted from September 2017 to June 2020 in Tehran, Iran, selected potential participants aged 18-65 years from a headache clinic at Sina Hospital (affiliated with Tehran University of Medical Sciences). Both episodic migraine and chronic migraine were diagnosed following the diagnostic criteria in the International Classification of Headache Disorders' third edition. Melatonin levels were measured according to the instructions of the ELISA kits. There were significant differences in the frequency of headache days and the duration of abortive medication usage between the two groups (P value < 0.001). Besides, analysis revealed significantly lower serum melatonin levels in patients with episodic ((80.45-45.06) 72.83) and chronic migraine ((154.34-63.34) 70.38, P value < 0.001) than in healthy controls (281.25-160.86) 280). Although no considerable differences were found between episodic and chronic migraine patients, the current study demonstrated that serum melatonin levels were substantially greater in healthy controls than in patients with migraine.
Identifiants
pubmed: 39358369
doi: 10.1038/s41598-024-73278-y
pii: 10.1038/s41598-024-73278-y
doi:
Substances chimiques
Melatonin
JL5DK93RCL
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
22883Informations de copyright
© 2024. The Author(s).
Références
Agosti, R. Migraine burden of disease: From the patient’s experience to a socio-economic view. Headache58(Suppl 1), 17–32. https://doi.org/10.1111/head.13301 (2018).
doi: 10.1111/head.13301
pubmed: 29697152
Pescador Ruschel, M. A. & De Jesus, O. In StatPearls (StatPearls Publishing Copyright © 2024, StatPearls Publishing LLC, 2024).
Stovner, L. et al. Global, regional, and national burden of migraine and tension-type headache, 1990–2016: A systematic analysis for the global burden of disease study 2016. Lancet Neurol.17, 954–976. https://doi.org/10.1016/S1474-4422(18)30322-3 (2018).
doi: 10.1016/S1474-4422(18)30322-3
Serrano, D. et al. Fluctuations in episodic and chronic migraine status over the course of 1 year: Implications for diagnosis, treatment and clinical trial design. J. Headache Pain18, 101. https://doi.org/10.1186/s10194-017-0787-1 (2017).
doi: 10.1186/s10194-017-0787-1
pubmed: 28980171
pmcid: 5628086
Togha, M. et al. Proteomics analysis revealed the presence of inflammatory and oxidative stress markers in the plasma of migraine patients during the pain period. Brain Res.1797, 148100. https://doi.org/10.1016/j.brainres.2022.148100 (2022).
doi: 10.1016/j.brainres.2022.148100
pubmed: 36174672
Durham, P. & Papapetropoulos, S. Biomarkers associated with migraine and their potential role in migraine management. Headache53, 1262–1277. https://doi.org/10.1111/head.12174 (2013).
doi: 10.1111/head.12174
pubmed: 23848170
Charles, A. The pathophysiology of migraine: Implications for clinical management. Lancet Neurol.17, 174–182. https://doi.org/10.1016/s1474-4422(17)30435-0 (2018).
doi: 10.1016/s1474-4422(17)30435-0
pubmed: 29229375
Andreou, A. P. & Edvinsson, L. Mechanisms of migraine as a chronic evolutive condition. J. Headache Pain20, 117. https://doi.org/10.1186/s10194-019-1066-0 (2019).
doi: 10.1186/s10194-019-1066-0
pubmed: 31870279
pmcid: 6929435
Togha, M., Ghorbani, Z., Ramazi, S., Zavvari, F. & Karimzadeh, F. Evaluation of serum levels of transient receptor potential cation channel subfamily V member 1, vasoactive intestinal polypeptide, and pituitary adenylate cyclase-activating polypeptide in chronic and episodic migraine: The possible role in migraine transformation. Front. Neurol.12, 770980. https://doi.org/10.3389/fneur.2021.770980 (2021).
doi: 10.3389/fneur.2021.770980
pubmed: 35002925
pmcid: 8733698
Togha, M., Razeghi Jahromi, S., Ghorbani, Z., Ghaemi, A. & Rafiee, P. An investigation of oxidant/antioxidant balance in patients with migraine: A case-control study. BMC Neurol.19, 323. https://doi.org/10.1186/s12883-019-1555-4 (2019).
doi: 10.1186/s12883-019-1555-4
pubmed: 31837702
pmcid: 6911287
Peres, M. F., Masruha, M. R., Zukerman, E., Moreira-Filho, C. A. & Cavalheiro, E. A. Potential therapeutic use of melatonin in migraine and other headache disorders. Expert Opin. Investig. Drugs15, 367–375. https://doi.org/10.1517/13543784.15.4.367 (2006).
doi: 10.1517/13543784.15.4.367
pubmed: 16548786
Kozak, H. H. et al. Sleep quality, morningness-eveningness preference, mood profile, and levels of serum melatonin in migraine patients: A case-control study. Acta Neurol. Belg.117, 111–119. https://doi.org/10.1007/s13760-016-0723-1 (2017).
doi: 10.1007/s13760-016-0723-1
pubmed: 27858294
Brun, J., Claustrat, B., Saddier, P. & Chazot, G. Nocturnal melatonin excretion is decreased in patients with migraine without aura attacks associated with menses. Cephalalgia15, 136–139. https://doi.org/10.1046/j.1468-2982.1995.015002136.x (1995) (discussion 179).
doi: 10.1046/j.1468-2982.1995.015002136.x
pubmed: 7641249
Claustrat, B. et al. Nocturnal plasma melatonin levels in migraine: A preliminary report. Headache29, 242–245. https://doi.org/10.1111/j.1526-4610.1989.hed22904242.x (1989).
doi: 10.1111/j.1526-4610.1989.hed22904242.x
pubmed: 2714976
Murialdo, G. et al. Urinary melatonin excretion throughout the ovarian cycle in menstrually related migraine. Cephalalgia14, 205–209. https://doi.org/10.1046/j.1468-2982.1994.014003205.x (1994).
doi: 10.1046/j.1468-2982.1994.014003205.x
pubmed: 7954740
Fathy, S. E., Abdallah, A. M. & Helal, R. Y. Assessment of serum level of melatonin in migraine: A case control study. Egypt. J. Neurol. Psychiatry Neurosurg.59, 1–7 (2023).
doi: 10.1186/s41983-023-00670-2
Zduńska, A., Cegielska, J., Zduński, S., Białobrzewski, M. & Kochanowski, J. Variability in melatonin concentration in blood serum of patients with episodic migraine: A pilot study. Neurol. Neurochir. Pol.55, 81–90. https://doi.org/10.5603/PJNNS.a2020.0095 (2021).
doi: 10.5603/PJNNS.a2020.0095
pubmed: 33306192
Lorente, L. et al. Serum melatonin levels are associated with mortality in patients with malignant middle cerebral artery infarction. J. Int. Med. Res.46, 3268–3277. https://doi.org/10.1177/0300060518775008 (2018).
doi: 10.1177/0300060518775008
pubmed: 29848129
pmcid: 6134645
Can, A. & Tuzer, O. C. The evaluation of melatonin levels in chronic spontaneous urticaria: A case control study. Allergy Asthma Proc.44, e29–e35. https://doi.org/10.2500/aap.2023.44.230044 (2023).
doi: 10.2500/aap.2023.44.230044
pubmed: 37714684
Peres, M. F., Zukerman, E., da Cunha Tanuri, F., Moreira, F. R. & Cipolla-Neto, J. Melatonin, 3 mg, is effective for migraine prevention. Neurology63, 757. https://doi.org/10.1212/01.wnl.0000134653.35587.24 (2004).
doi: 10.1212/01.wnl.0000134653.35587.24
pubmed: 15326268
Alstadhaug, K. B., Odeh, F., Salvesen, R. & Bekkelund, S. I. Prophylaxis of migraine with melatonin: A randomized controlled trial. Neurology75, 1527–1532. https://doi.org/10.1212/WNL.0b013e3181f9618c (2010).
doi: 10.1212/WNL.0b013e3181f9618c
pubmed: 20975054
Bougea, A., Spantideas, N., Lyras, V., Avramidis, T. & Thomaidis, T. Melatonin 4 mg as prophylactic therapy for primary headaches: A pilot study. Funct. Neurol.31, 33–37. https://doi.org/10.11138/fneur/2016.31.1.033 (2016).
doi: 10.11138/fneur/2016.31.1.033
pubmed: 27027892
pmcid: 4819816
Gonçalves, A. L. et al. Randomised clinical trial comparing melatonin 3 mg, amitriptyline 25 mg and placebo for migraine prevention. J. Neurol. Neurosurg. Psychiatry87, 1127–1132. https://doi.org/10.1136/jnnp-2016-313458 (2016).
doi: 10.1136/jnnp-2016-313458
pubmed: 27165014
Zduńska, A., Cegielska, J. & Domitrz, I. The pathogenetic role of melatonin in migraine and its theoretic implications for pharmacotherapy: A brief overview of the research. Nutrients14, 3335. https://doi.org/10.3390/nu14163335 (2022).
doi: 10.3390/nu14163335
pubmed: 36014841
pmcid: 9415653
Sati, V., Jauhari, R., Rao, N., Godiyal, P. & Babbar, A. Melatonin: Role in the prophylaxis of migraine. J. Appl. Pharm. Sci. Res.5, 17–27 (2022).
doi: 10.31069/japsr.v5i2.03
Noseda, R. & Burstein, R. Migraine pathophysiology: Anatomy of the trigeminovascular pathway and associated neurological symptoms, cortical spreading depression, sensitization, and modulation of pain. Pain154(Suppl 1), S44-53. https://doi.org/10.1016/j.pain.2013.07.021 (2013).
doi: 10.1016/j.pain.2013.07.021
pubmed: 23891892
Durham, P. L. Calcitonin gene-related peptide (CGRP) and migraine. Headache46(Suppl 1), S3-8. https://doi.org/10.1111/j.1526-4610.2006.00483.x (2006).
doi: 10.1111/j.1526-4610.2006.00483.x
pubmed: 16927957
pmcid: 3134175
Vogler, B., Rapoport, A. M., Tepper, S. J., Sheftell, F. & Bigal, M. E. Role of melatonin in the pathophysiology of migraine: Implications for treatment. CNS Drugs20, 343–350. https://doi.org/10.2165/00023210-200620050-00001 (2006).
doi: 10.2165/00023210-200620050-00001
pubmed: 16696576
Ansari, M., Karkhaneh, A., Kheirollahi, A., Emamgholipour, S. & Rafiee, M. H. The effect of melatonin on gene expression of calcitonin gene-related peptide and some proinflammatory mediators in patients with pure menstrual migraine. Acta Neurol. Belg.117, 677–685. https://doi.org/10.1007/s13760-017-0803-x (2017).
doi: 10.1007/s13760-017-0803-x
pubmed: 28584969
Puliappadamb, H. M., Maiti, R., Mishra, A., Jena, M. & Mishra, B. R. Efficacy and safety of melatonin as prophylaxis for migraine in adults: A meta-analysis. J. Oral Fac. Pain Headache36, 207–219. https://doi.org/10.11607/ofph.3211 (2022).
doi: 10.11607/ofph.3211
Ebrahimi-Monfared, M., Sharafkhah, M., Abdolrazaghnejad, A., Mohammadbeigi, A. & Faraji, F. Use of melatonin versus valproic acid in prophylaxis of migraine patients: A double-blind randomized clinical trial. Restor. Neurol. Neurosci.35, 385–393. https://doi.org/10.3233/rnn-160704 (2017).
doi: 10.3233/rnn-160704
pubmed: 28800342
Reiter, R. J., Calvo, J. R., Karbownik, M., Qi, W. & Tan, D. X. Melatonin and its relation to the immune system and inflammation. Ann. N. Y. Acad. Sci.917, 376–386. https://doi.org/10.1111/j.1749-6632.2000.tb05402.x (2000).
doi: 10.1111/j.1749-6632.2000.tb05402.x
pubmed: 11268363
Li, S. J. et al. Melatonin inhibits NF-κB/CREB/Runx2 signaling and alleviates aortic valve calcification. Front. Cardiovasc. Med.9, 885293. https://doi.org/10.3389/fcvm.2022.885293 (2022).
doi: 10.3389/fcvm.2022.885293
pubmed: 35795373
pmcid: 9251177
Muñoz-Jurado, A. et al. Melatonin and multiple sclerosis: Antioxidant, anti-inflammatory and immunomodulator mechanism of action. Inflammopharmacology30, 1569–1596. https://doi.org/10.1007/s10787-022-01011-0 (2022).
doi: 10.1007/s10787-022-01011-0
pubmed: 35665873
pmcid: 9167428
Huang, J. et al. Melatonin, an endogenous hormone, modulates Th17 cells via the reactive-oxygen species/TXNIP/HIF-1α axis to alleviate autoimmune uveitis. J. Neuroinflamm.19, 124. https://doi.org/10.1186/s12974-022-02477-z (2022).
doi: 10.1186/s12974-022-02477-z
Chen, J. et al. Melatonin attenuates prostatic inflammation and pelvic pain via Sirt1-dependent inhibition of the NLRP3 inflammasome in an EAP mouse model. Prostate81, 1179–1190. https://doi.org/10.1002/pros.24214 (2021).
doi: 10.1002/pros.24214
pubmed: 34418127
Neeb, L. et al. Corticosteroids alter CGRP and melatonin release in cluster headache episodes. Cephalalgia35, 317–326. https://doi.org/10.1177/0333102414539057 (2015).
doi: 10.1177/0333102414539057
pubmed: 24958681
Headache Classification Committee of the International Headache Society (IHS). The international classification of headache disorders 3rd edition. Cephalalgia38, 1–211. https://doi.org/10.1177/0333102417738202 (2018).
doi: 10.1177/0333102417738202
The international classification of headache disorders, 3rd edition (beta version). Cephalalgia33, 629-808 (2013). https://doi.org/10.1177/0333102413485658
(2021), G. D. Bioanalytical Method Validation Guidance for Industry (FDA, 2018).